Alphyn Biologics Reports Encouraging Interim Results of Phase 2a Trial for Atopic Dermatitis with Secondary Bacterial Infection

Alphyn Biologics, a clinical-stage dermatology company, has announced promising interim findings from the Phase 2a trial of their topical treatment, AB-101a, for atopic dermatitis (AD) with secondary bacterial infection. The results indicate that AB-101a is effectively addressing all efficacy and safety measures across mild, moderate, and severe cases of AD. This therapeutic candidate is success..